Overview Financials News + Filings IR Vault Key Docs Charts Transactions Holdings Ownership Insiders
|
|
ABIOMED INC (ABMD)
|
Add to portfolio |
|
|
|
| Price: |
$366.29
| | Metrics |
| OS: |
45.5
|
M
| |
14
|
% ROE
|
| Market cap: |
$16.7
|
B
| |
21
|
% ROIC
|
|
Net cash:
|
$180
|
M
| |
$3.97
|
per share
|
|
EV:
|
$16.5
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$356
|
M
| |
46.3
|
x EV/EBITDA
|
|
EBIT
|
$328
|
M
| |
50.3
|
x EV/EBIT
|
| EPS |
$4.74
| |
77.3
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Mar-31-22 | Mar-31-21 | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 | Mar-31-15 |
| Revenues | 1,031.8 | 847.5 | 840.9 | 769.4 | 593.7 | 445.3 | 329.5 | 230.3 |
| Revenue growth | 21.7% | 0.8% | 9.3% | 29.6% | 33.3% | 35.1% | 43.1% | 25.4% |
| Cost of goods sold | 188.2 | 161.9 | 151.3 | 129.6 | 98.6 | 70.6 | 50.4 | 39.9 |
| Gross profit | 843.6 | 685.6 | 689.6 | 639.9 | 495.2 | 374.7 | 279.1 | 190.4 |
| Gross margin | 81.8% | 80.9% | 82.0% | 83.2% | 83.4% | 84.1% | 84.7% | 82.7% |
| Selling, general and administrative | 116.0 | 456.1 | 440.4 | 321.6 | 262.7 | 218.2 | 164.3 | 125.7 |
| Research and development | | | | 93.5 | 75.3 | 66.4 | 49.8 | 36.0 |
| EBIT | 326.7 | 232.0 | 249.2 | 224.8 | 157.1 | 90.1 | 65.1 | 28.7 |
| EBIT margin | 31.7% | 27.4% | 29.6% | 29.2% | 26.5% | 20.2% | 19.8% | 12.4% |
| Pre-tax income | 190.6 | 288.2 | 256.8 | 263.4 | 160.4 | 91.3 | 65.8 | 28.8 |
| Income taxes | 54.1 | 62.7 | 53.8 | 4.3 | 48.3 | 39.2 | 27.7 | -84.9 |
| Tax rate | 28.4% | 21.8% | 21.0% | 1.6% | 30.1% | 42.9% | 42.1% | |
| Net income | 136.5 | 225.5 | 203.0 | 259.0 | 112.2 | 52.1 | 38.1 | 113.7 |
| Net margin | 13.2% | 26.6% | 24.1% | 33.7% | 18.9% | 11.7% | 11.6% | 49.4% |
| |
| Diluted EPS | $2.98 | $4.94 | $4.43 | $5.61 | $2.45 | $1.17 | $0.85 | $2.65 |
| Shares outstanding (diluted) | 45.9 | 45.7 | 45.8 | 46.2 | 45.8 | 44.7 | 44.9 | 42.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|